Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Luk, Sze Ue ^b   Lee, Terence Kin Wah ^b   Liu, Ji ^a   Lee, Davy Tak Wing ^b   Chiu, Yung Tuen ^b   Ma, Stephanie ^b   Ng, Irene Oi Lin ^b   Wong, Yong Chuan ^b   Chan, Franky Leung ^c   Ling, Ming Tat ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN; PLANT MEDICINAL PRODUCT; POLYSACCHAROPEPTIDE; UNCLASSIFIED DRUG; POLYSACCHARIDE PEPTIDE; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER PREVENTION; CANCER STEM CELL; CARCINOGENICITY; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORIOLUS VERSICOLOR; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG DOSE COMPARISON; MALE; MOUSE; MUSHROOM; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; ANIMAL; CHEMOPROPHYLAXIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; HUMAN; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE; TREATMENT OUTCOME;

BASIDIOMYCOTA; MUS; MUS MUSCULUS; TRAMETES VERSICOLOR;

ANIMALS; CHEMOPREVENTION; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TREATMENT OUTCOME;

EID: 79956100438     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019804     Document Type: Article

References (38)

1. Pomerantz M, Kantoff P, (2007) Advances in the treatment of prostate cancer. Annu Rev Med 58: 205-220.
2. Sarvis JA, Thompson IM, (2008) Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep 10: 529-532.
3. Musquera M, Fleshner NE, Finelli A, Zlotta AR, (2008) The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 8: 1073-1079.
4. Khan N, Afaq F, Mukhtar H, (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510.
5. Singh RP, Agarwal R, (2006) Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 13: 751-778.
6. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, et al. (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440-446.
7. O'Brien CA, Kreso A, Jamieson CH, (2010) Cancer stem cells and self-renewal. Clin Cancer Res 16: 3113-3120.
8. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, et al. (2009) Therapeutic implications of Cancer Initiating Cells. Expert Opin Biol Ther 9: 1005-1016.
9. Luk SU, Yap WN, Chiu YT, Lee DT, Ma S, et al. (2011) Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int J Cancer.
10. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. (2011) Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology.
11. Jimenez-Medina E, Berruguilla E, Romero I, Algarra I, Collado A, et al. (2008) The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 8: 78.
12. Sakagami H, Aoki T, Simpson A, Tanuma S, (1991) Induction of immunopotentiation activity by a protein-bound polysaccharide, PSK (review). Anticancer Res 11: 993-999.
13. Ng TB, (1998) A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 30: 1-4.
14. Bisson I, Prowse DM, (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res.
15. Miki J, Furusato B, Li H, Gu Y, Takahashi H, et al. (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161.
16. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106: 268-273.
17. Duan W, Gabril MY, Moussa M, Chan FL, Sakai H, et al. (2005) Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene 24: 1510-1524.
18. Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, et al. (2002) Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 9: 1589-1599.
19. Joniau S, Goeman L, Pennings J, Van Poppel H, (2005) Prostatic intraepithelial neoplasia (PIN): importance and clinical management. Eur Urol 48: 379-385.
20. Ho CY, Kim CF, Leung KN, Fung KP, Tse TF, et al. (2005) Differential anti-tumor activity of coriolus versicolor (Yunzhi) extract through p53- and/or Bcl-2-dependent apoptotic pathway in human breast cancer cells. Cancer Biol Ther 4: 638-644.
21. Chow LW, Lo CS, Loo WT, Hu XC, Sham JS, (2003) Polysaccharide peptide mediates apoptosis by up-regulating p21 gene and down-regulating cyclin D1 gene. Am J Chin Med 31: 1-9.
22. Wan JM, Sit WH, Louie JC, (2008) Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30. Int J Oncol 32: 689-699.
23. Dong Y, Kwan CY, Chen ZN, Yang MM, (1996) Antitumor effects of a refined polysaccharide peptide fraction isolated from Coriolus versicolor: in vitro and in vivo studies. Res Commun Mol Pathol Pharmacol 92: 140-148.
24. Hsieh TC, Wu JM, (2001) Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells. Int J Oncol 18: 81-88.
25. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
26. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL, (2008) CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98: 756-765.
27. Wei C, Guomin W, Yujun L, Ruizhe Q, (2007) Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 6: 763-768.
28. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG, (2008) PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68: 1820-1825.
29. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708.
30. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, et al. (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7: e1000121.
31. Reynolds BA, Weiss S, (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707-1710.
32. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
33. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337.
34. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, et al. (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10.
35. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
36. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, et al. (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67: 3560-3564.
37. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, et al. (2003) Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22: 4498-4508.
38. Howard EW, Ling MT, Chua CW, Cheung HW, Wang X, et al. (2007) Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer. Clin Cancer Res 13: 1847-1856.